Related Experiment Video

Updated: Nov 3, 2025

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

823

Does Cefiderocol Have a Potential Role in Cystic Fibrosis Pulmonary Exacerbation Management?

Elizabeth Marie Gavioli1, Nerli Guardado1, Farah Haniff1

  • 1Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Brooklyn, New York, USA.

Microbial Drug Resistance (Larchmont, N.Y.)
|June 2, 2021
PubMed

Insights

Cefiderocol offers a new antibiotic option for cystic fibrosis (CF) patients facing multidrug-resistant (MDR) gram-negative infections. It shows potential against key CF pathogens when other treatments fail due to resistance or rapid decline.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Pharmacology

Background:

  • Cystic fibrosis (CF) patients frequently experience pulmonary exacerbations.
  • Antimicrobial resistance is a growing concern in CF pulmonary infections.
  • Novel antibiotics are needed to combat multidrug-resistant (MDR) pathogens in CF.

Purpose of the Study:

  • To review the potential role of cefiderocol against common MDR gram-negative pathogens in CF.
  • To evaluate cefiderocol as a therapeutic option for CF patients with limited treatment choices.

Main Methods:

  • Literature review of cefiderocol's activity against relevant CF pathogens.
  • Analysis of minimum inhibitory concentrations (MICs) for key bacteria.
  • Assessment of cefiderocol's potential clinical utility in CF based on existing data.

Main Results:

  • Cefiderocol demonstrates in vitro activity against MDR *Pseudomonas aeruginosa*, *Stenotrophomonas maltophilia*, *Achromobacter xylosoxidans*, and *Burkholderia cepacia* complex.
  • The antibiotic is effective against pathogens with MICs of ≤4 mg/L.
  • No in vivo evidence in CF patients is currently available.

Conclusions:

  • Cefiderocol represents a potential therapeutic option for CF patients infected with MDR gram-negative bacteria.
  • It may be considered when alternative treatments are lacking due to MDR organisms or rapid pulmonary decline.
  • Further in vivo studies in the CF population are warranted.
Keywords:
cefiderocolcystic fibrosisdrug resistanceinfectionpulmonary exacerbation

More Related Videos

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

778
The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections06:57

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

Published on: May 8, 2017

9.3K

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
297
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
490
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
511
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
358
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
538
Chest Physiotherapy01:24

Chest Physiotherapy

Chest Physiotherapy (CPT) is a therapeutic technique used in respiratory care to improve ventilation, clear bronchial secretions, and enhance the efficiency of respiratory muscles. This therapy includes three primary procedures: postural drainage, percussion, and vibration. It can be performed on spontaneously breathing patients and those who are intubated and mechanically ventilated.
Purpose
CPT is primarily used for patients with excessive bronchial secretions who have difficulty clearing...
979